T1	Disorder 10 25	Pulmonary edema
N1 	Reference T1 UMLS:C0034063	Pulmonary edema
T2	Pharmacological_substance 51 63	epoprostenol
N1000 	Reference T2 MeSH:D011464	epoprostenol
T3	Disorder 82 104	pulmonary hypertension
N2 	Reference T3 UMLS:C0020542	pulmonary hypertension
T4	Disorder 109 128	limited scleroderma
N3 	Reference T4 UMLS:C0748540	limited scleroderma
T5	Pharmacological_substance 131 143	Epoprostenol
N1001 	Reference T5 MeSH:D011464	Epoprostenol
T6	Pharmacological_substance 145 157	prostacyclin
N1002 	Reference T6 MeSH:D011464	prostacyclin
T7	Disorder 198 228	primary pulmonary hypertension
N4 	Reference T7 UMLS:C1971646	primary pulmonary hypertension
N5 	Reference T7 UMLS:C0152171	primary pulmonary hypertension
T8	Disorder 264 301	other forms of pulmonary hypertension
T9	Pharmacological_substance 543 555	epoprostenol
N1003 	Reference T9 MeSH:D011464	epoprostenol
T10	Disorder 566 581	pulmonary edema
N6 	Reference T10 UMLS:C0034063	pulmonary edema
T11	Disorder 601 623	pulmonary hypertension
N7 	Reference T11 UMLS:C0020542	pulmonary hypertension
T12	Disorder 640 659	limited scleroderma
N8 	Reference T12 UMLS:C0748540	limited scleroderma
T13	Pharmacological_substance 740 752	epoprostenol
N1004 	Reference T13 MeSH:D011464	epoprostenol
T14	Subject 67 76	a patient
T17	Disorder 316 327	scleroderma
N9 	Reference T17 UMLS:C0011644	scleroderma
T19	Subject 586 595	a patient
T21	Coreferring_mention 358 373	this medication
T23	Disorder 393 414	serious complications
N10 	Reference T23 UMLS:C0009566	serious complications
T18	Speculation_cue 245 260	being evaluated
T26	Manner_cue 386 392	minor;
T27	Manner_cue 505 521	life threatening
